A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2025
The objectives of this study are to evaluate the glycemic efficacy, safety, and tolerability of ersodetug for treatment of hypoglycemia in patients with Tumor-Associated Hyperinsulinism (tHI).
Epistemonikos ID: 4da8f47da1e1c573e5bd5b41f22a9816e632b447
First added on: Mar 27, 2025